Cargando…

Pomalidomide in Patients With Relapsed and/or Refractory Multiple Myeloma: A Prospective Study Within the Nationwide Netherlands Cancer Registry

Patients with relapsed and/or refractory multiple myeloma (RRMM) generally have limited treatment options and a poor prognosis. Previous trials demonstrated that pomalidomide combined with low-dose dexamethasone (Pd) is effective in these patients with significant responses and improved progression-...

Descripción completa

Detalles Bibliográficos
Autores principales: Wester, Ruth, Dinmohamed, Avinash G., van der Holt, Bronno, Zweegman, Sonja, Minnema, Monique, Croockewit, Sandra, Levin, Mark-David, Libourel, Eduard, de Waal, Esther, Sonneveld, Pieter, Cornelissen, Jan, Blijlevens, Nicole, Broijl, Annemiek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797586/
https://www.ncbi.nlm.nih.gov/pubmed/35106452
http://dx.doi.org/10.1097/HS9.0000000000000683
_version_ 1784641587490324480
author Wester, Ruth
Dinmohamed, Avinash G.
van der Holt, Bronno
Zweegman, Sonja
Minnema, Monique
Croockewit, Sandra
Levin, Mark-David
Libourel, Eduard
de Waal, Esther
Sonneveld, Pieter
Cornelissen, Jan
Blijlevens, Nicole
Broijl, Annemiek
author_facet Wester, Ruth
Dinmohamed, Avinash G.
van der Holt, Bronno
Zweegman, Sonja
Minnema, Monique
Croockewit, Sandra
Levin, Mark-David
Libourel, Eduard
de Waal, Esther
Sonneveld, Pieter
Cornelissen, Jan
Blijlevens, Nicole
Broijl, Annemiek
author_sort Wester, Ruth
collection PubMed
description Patients with relapsed and/or refractory multiple myeloma (RRMM) generally have limited treatment options and a poor prognosis. Previous trials demonstrated that pomalidomide combined with low-dose dexamethasone (Pd) is effective in these patients with significant responses and improved progression-free survival (PFS). Pd has been approved in RRMM patients who received ≥2 prior lines of therapy. Here, we present the results of a population-based study of patients with RRMM treated with Pd in The Netherlands from time of pomalidomide approval. Using the nationwide Netherlands Cancer Registry, data from all nontrial patients with RRMM treated with Pd were collected. Data were analyzed of response, PFS, and overall survival (OS). A total of 237 patients were included in this analysis. Previous treatment consisted of a proteasome inhibitor in 227 patients (96%) and/or an immune-modulating agent in 235 patients (99%). One hundred forty patients (59%) were refractory to an immune-modulating agent in their last line of therapy. Median time from diagnosis to treatment with Pd was 4.9 years (interquartile range, 2.7–7.9), and the median number of prior treatments was 4 (interquartile range, 3–5). Median PFS and OS for all patients were 3.6 months (95% confidence interval [CI], 3.1–3.8) and 7.7 months (95% CI, 5.7–9.7), respectively. For patients achieving ≥PR, median PFS and OS were 10.6 months (95% CI, 8.3–12.9) and 16.3 months (95% CI, 13.6–23.2), respectively. This nationwide, population-based registry study confirms data shown in pivotal clinical trials on Pd. PFS in this analysis is comparable to PFS observed in those clinical trials.
format Online
Article
Text
id pubmed-8797586
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-87975862022-01-31 Pomalidomide in Patients With Relapsed and/or Refractory Multiple Myeloma: A Prospective Study Within the Nationwide Netherlands Cancer Registry Wester, Ruth Dinmohamed, Avinash G. van der Holt, Bronno Zweegman, Sonja Minnema, Monique Croockewit, Sandra Levin, Mark-David Libourel, Eduard de Waal, Esther Sonneveld, Pieter Cornelissen, Jan Blijlevens, Nicole Broijl, Annemiek Hemasphere Article Patients with relapsed and/or refractory multiple myeloma (RRMM) generally have limited treatment options and a poor prognosis. Previous trials demonstrated that pomalidomide combined with low-dose dexamethasone (Pd) is effective in these patients with significant responses and improved progression-free survival (PFS). Pd has been approved in RRMM patients who received ≥2 prior lines of therapy. Here, we present the results of a population-based study of patients with RRMM treated with Pd in The Netherlands from time of pomalidomide approval. Using the nationwide Netherlands Cancer Registry, data from all nontrial patients with RRMM treated with Pd were collected. Data were analyzed of response, PFS, and overall survival (OS). A total of 237 patients were included in this analysis. Previous treatment consisted of a proteasome inhibitor in 227 patients (96%) and/or an immune-modulating agent in 235 patients (99%). One hundred forty patients (59%) were refractory to an immune-modulating agent in their last line of therapy. Median time from diagnosis to treatment with Pd was 4.9 years (interquartile range, 2.7–7.9), and the median number of prior treatments was 4 (interquartile range, 3–5). Median PFS and OS for all patients were 3.6 months (95% confidence interval [CI], 3.1–3.8) and 7.7 months (95% CI, 5.7–9.7), respectively. For patients achieving ≥PR, median PFS and OS were 10.6 months (95% CI, 8.3–12.9) and 16.3 months (95% CI, 13.6–23.2), respectively. This nationwide, population-based registry study confirms data shown in pivotal clinical trials on Pd. PFS in this analysis is comparable to PFS observed in those clinical trials. Lippincott Williams & Wilkins 2022-01-27 /pmc/articles/PMC8797586/ /pubmed/35106452 http://dx.doi.org/10.1097/HS9.0000000000000683 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Article
Wester, Ruth
Dinmohamed, Avinash G.
van der Holt, Bronno
Zweegman, Sonja
Minnema, Monique
Croockewit, Sandra
Levin, Mark-David
Libourel, Eduard
de Waal, Esther
Sonneveld, Pieter
Cornelissen, Jan
Blijlevens, Nicole
Broijl, Annemiek
Pomalidomide in Patients With Relapsed and/or Refractory Multiple Myeloma: A Prospective Study Within the Nationwide Netherlands Cancer Registry
title Pomalidomide in Patients With Relapsed and/or Refractory Multiple Myeloma: A Prospective Study Within the Nationwide Netherlands Cancer Registry
title_full Pomalidomide in Patients With Relapsed and/or Refractory Multiple Myeloma: A Prospective Study Within the Nationwide Netherlands Cancer Registry
title_fullStr Pomalidomide in Patients With Relapsed and/or Refractory Multiple Myeloma: A Prospective Study Within the Nationwide Netherlands Cancer Registry
title_full_unstemmed Pomalidomide in Patients With Relapsed and/or Refractory Multiple Myeloma: A Prospective Study Within the Nationwide Netherlands Cancer Registry
title_short Pomalidomide in Patients With Relapsed and/or Refractory Multiple Myeloma: A Prospective Study Within the Nationwide Netherlands Cancer Registry
title_sort pomalidomide in patients with relapsed and/or refractory multiple myeloma: a prospective study within the nationwide netherlands cancer registry
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797586/
https://www.ncbi.nlm.nih.gov/pubmed/35106452
http://dx.doi.org/10.1097/HS9.0000000000000683
work_keys_str_mv AT westerruth pomalidomideinpatientswithrelapsedandorrefractorymultiplemyelomaaprospectivestudywithinthenationwidenetherlandscancerregistry
AT dinmohamedavinashg pomalidomideinpatientswithrelapsedandorrefractorymultiplemyelomaaprospectivestudywithinthenationwidenetherlandscancerregistry
AT vanderholtbronno pomalidomideinpatientswithrelapsedandorrefractorymultiplemyelomaaprospectivestudywithinthenationwidenetherlandscancerregistry
AT zweegmansonja pomalidomideinpatientswithrelapsedandorrefractorymultiplemyelomaaprospectivestudywithinthenationwidenetherlandscancerregistry
AT minnemamonique pomalidomideinpatientswithrelapsedandorrefractorymultiplemyelomaaprospectivestudywithinthenationwidenetherlandscancerregistry
AT croockewitsandra pomalidomideinpatientswithrelapsedandorrefractorymultiplemyelomaaprospectivestudywithinthenationwidenetherlandscancerregistry
AT levinmarkdavid pomalidomideinpatientswithrelapsedandorrefractorymultiplemyelomaaprospectivestudywithinthenationwidenetherlandscancerregistry
AT liboureleduard pomalidomideinpatientswithrelapsedandorrefractorymultiplemyelomaaprospectivestudywithinthenationwidenetherlandscancerregistry
AT dewaalesther pomalidomideinpatientswithrelapsedandorrefractorymultiplemyelomaaprospectivestudywithinthenationwidenetherlandscancerregistry
AT sonneveldpieter pomalidomideinpatientswithrelapsedandorrefractorymultiplemyelomaaprospectivestudywithinthenationwidenetherlandscancerregistry
AT cornelissenjan pomalidomideinpatientswithrelapsedandorrefractorymultiplemyelomaaprospectivestudywithinthenationwidenetherlandscancerregistry
AT blijlevensnicole pomalidomideinpatientswithrelapsedandorrefractorymultiplemyelomaaprospectivestudywithinthenationwidenetherlandscancerregistry
AT broijlannemiek pomalidomideinpatientswithrelapsedandorrefractorymultiplemyelomaaprospectivestudywithinthenationwidenetherlandscancerregistry